Lantern Pharma Inc. financial data

Symbol
LTRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1920 Mckinney Avenue, 7 Th Floor, Dallas, TX
State of incorporation
TX
Fiscal year end
December 31
Former names
Lantern Pharma (to 1/14/2019)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 788 % -57%
Debt-to-equity 14.6 % +144%
Return On Equity -72.6 % -113%
Return On Assets -63.4 % -96.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares +0.4%
Common Stock, Shares, Outstanding 10.8M shares +0.59%
Entity Public Float 44.3M USD -15.8%
Common Stock, Value, Issued 1.08K USD +0.56%
Weighted Average Number of Shares Outstanding, Basic 10.8M shares -0.74%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares -0.74%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.1M USD +35.6%
General and Administrative Expense 6.09M USD +1.8%
Operating Income (Loss) -22.2M USD -24.3%
Net Income (Loss) Attributable to Parent -20.8M USD -30.2%
Earnings Per Share, Basic -1.93 USD/shares -31.3%
Earnings Per Share, Diluted -1.93 USD/shares -31.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.51M USD -65.8%
Marketable Securities, Current 16.5M USD -14.8%
Assets, Current 25.2M USD -41.7%
Property, Plant and Equipment, Net 47.4K USD -8.99%
Operating Lease, Right-of-Use Asset 240K USD +5.12%
Other Assets, Noncurrent 36.7K USD +42%
Assets 25.6M USD -41.4%
Liabilities, Current 4.33M USD +61.7%
Operating Lease, Liability, Noncurrent 52.8K USD -14.1%
Liabilities 4.38M USD +60%
Accumulated Other Comprehensive Income (Loss), Net of Tax 154K USD
Retained Earnings (Accumulated Deficit) -76M USD -37.6%
Stockholders' Equity Attributable to Parent 21.2M USD -48.2%
Liabilities and Equity 25.6M USD -41.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.07M USD +18.3%
Net Cash Provided by (Used in) Financing Activities 54.7K USD
Net Cash Provided by (Used in) Investing Activities -556K USD +42.1%
Common Stock, Shares Authorized 25M shares 0%
Common Stock, Shares, Issued 10.8M shares +0.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.58M USD +24.2%
Deferred Tax Assets, Valuation Allowance 17.8M USD +41.7%
Deferred Tax Assets, Gross 17.8M USD +41.7%
Operating Lease, Liability 244K USD +3.92%
Payments to Acquire Property, Plant, and Equipment 2.22K USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.5M USD -30.7%
Lessee, Operating Lease, Liability, to be Paid 260K USD +5.3%
Operating Lease, Liability, Current 191K USD +10.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54.7K USD -12.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 205K USD +11.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +27.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16.4K USD +31.1%
Deferred Tax Assets, Operating Loss Carryforwards 9.35M USD +26.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 45K USD +7.14%
Additional Paid in Capital 97.1M USD +0.83%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4.06K USD +18.8%
Deferred Tax Assets, Net of Valuation Allowance 6.13K USD +59.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%